

A Comprehensive Review on Hypothyroidism: Pathophysiology, Diagnosis, Management and Complications

Ms. Dnyaneshwari Suresh Kalane*, **Dr. Priyanka Kundlik Sabale**, **Dr. Jaydeep Babasaheb Pawar**
Prof. Amarsinh Sureshrao Devdhe, **Mr. Abhay Vishal Dhumal**
Department of Pharmacology, Shantiniketan College of Pharmacy, Dhotre Bk, Tal-Parner, Dist-
Ahilyanagar, Maharashtra, India, 413304
Corresponding Author- Ms. Dnyaneshwari Suresh Kalane
Email: dkalane2003@gmail.com

ABSTRACT:

Hypothyroidism is a common endocrine disorder characterized by deficient production of thyroid hormones, leading to widespread metabolic and physiological disturbances. Thyroid hormones—primarily T₃ and T₄—play a crucial role in regulating growth, metabolism, cardiovascular function, neurological activity, and gastrointestinal motility. This review provides a comprehensive understanding of thyroid hormone synthesis, metabolism, transport, and physiological actions, followed by an in-depth discussion of hypothyroidism, including its types, causes, risk factors, clinical manifestations, and diagnostic criteria. Primary hypothyroidism arises from intrinsic thyroid gland dysfunction, whereas secondary hypothyroidism results from inadequate stimulation of the thyroid gland due to pituitary or hypothalamic defects. The review further summarizes the therapeutic strategies such as levothyroxine replacement therapy, management of associated pituitary deficiencies, and monitoring approaches. Additionally, the systemic complications of hypothyroidism—especially cardiovascular, metabolic, gastrointestinal, and pediatric implications—are extensively outlined. This paper aims to consolidate current knowledge and provide an updated, clear, and clinically relevant overview of hypothyroidism for healthcare professionals and learners.

KEY WORDS: Hypothyroidism, Thyroid Hormone, T₃ and T₄ Metabolism, Anti-Hypothyroid Drugs, Endocrine Disorder, Complications of Hypothyroidism, T₃ and T₄ Metabolism

INTRODUCTION [1-4]:

• Hormone-

Hormones are chemical messengers produced by glands in the body that travel through the bloodstream to regulate various functions. They control and coordinate processes like growth, metabolism, reproduction, and mood, affecting cells and organs throughout the body. Examples include insulin, which regulates blood sugar, and Estrogen which is a key reproductive hormone.

Various types of Hormones-

- Estrogen
- Insulin
- Thyroid Hormones
- Cortisol
- Growth Hormone
- Testosterone
- Progesterone
- Adrenaline

Thyroid

Thyroid refers to a butterfly-shaped endocrine gland at the base of the neck that produces hormones regulating your body's metabolism, growth, and temperature.




Fig.No-01 Thyroid

Thyroid Hormone-

Thyroid hormone is the hormone that's mainly responsible for controlling the speed of your body's Metabolism In infants, thyroid hormone is critical for brain development. Thyroid is a small, butterfly-shaped gland located at the front neck under skin, makes and releases thyroid hormone. It's a part of Endocrine System

There are types of Thyroid Hormone

1. T₃
2. T₄
3. TSH




Fig No 02– Thyroid Hormone

1. T₃ (triiodothyronine)

Thyroid gland produces tri-iodothyronine (T₃) which is the active thyroid hormone. It is involved in most of the physiological processes in the body like growth, metabolism and heart rate. T₃ is released quickly due to its lesser affinity for plasma proteins and its effect is faster than thyroxine (T₄).

- **Metabolism-**

T₃ is the biologically active thyroid hormone. Although some T₃ is secreted directly by the thyroid gland, most of it actually comes from peripheral conversion of T₄ (thyroxine). Its metabolism includes production, transport, and intracellular metabolism

1. Production of T₃

A. Direct secretion from the thyroid

- A. The thyroid gland secretes ~20% of circulating T₃.
- B. T₃ secretion is regulated by TSH (thyroid-stimulating hormone).

B. Peripheral conversion from T₄

- C. About 80% of circulating T₃ is generated in tissues through deiodination of T₄ via deiodinase enzymes:

Deiodinase	Location	Function
Type 1 (D1)	Liver, kidney, thyroid	Converts T ₄ → T ₃ (major source of plasma T ₃)
Type 2 (D2)	Brain, pituitary, brown fat, skeletal muscle	Converts T ₄ → T ₃ locally for cellular use
Type 3 (D3)	Brain, skin, placenta, fetal tissues	Inactivates T ₄ → rT ₃ and T ₃ → T ₂

2. Transport in the Blood

T₃ is mostly bound to transport proteins:

Transport Protein	% of Binding
TBG (thyroxine-binding globulin)	~70%
Transthyretin (TTR)	~20%
Albumin	~10%

Only 0.3% of T₃ is free, and free T₃ is the biologically active fraction

▪ Intracellular Metabolism

Inside cells, T₃ can be:

A. Activated

Not applicable—T₃ is already the active form (activation applies mainly to T₄).

B. Inactivated

Primarily via D3 deiodinase:

- T₃ → T₂ (inactive)

Storage:

1. Most T₃ is produced outside the Thyroid

- About 80–90% of circulating T₃ is formed in peripheral tissues (like liver, kidney) by deiodination of T₄.
- Because of this, the body does not store T₃ significantly in the gland.

2. Binding in Blood

In circulation, T₃ is loosely bound to proteins:

- Thyroxine-binding globulin (TBG)
- Transthyretin
- Albumin

2. T₄ (thyroxine)

Thyroid gland produces thyroxine (T₄) in the body by the regulation of hypothalamus and the pituitary gland. Thyroxine (T₄) must be converted to triiodothyronine (T₃) to become active by either

type 1 (D1) or type 2 (D2) deiodinase enzyme. Iodine is the major constituent that is required for the formation of thyroxine. To synthesize normal amount of thyroxine iodide is needed from the ingested iodine.

- **Metabolism-**

T₄ is the major hormone produced by the thyroid gland, but it is biologically less active. Its metabolism converts it into active or inactive forms.

1. Deiodination (Most Important Pathway)

About 80–90% of T₄ metabolism occurs via deiodination in peripheral tissues (liver, kidney, muscle, and brain).

There are three types of deiodinase enzymes:

A. Type I (D1)

- Found in: liver, kidney, thyroid
- Converts:
 - T₄ → T₃ (active)
 - T₄ → rT₃ (reverse T₃, inactive)
- Provides major circulating T₃.

B. Type II (D2)

- Found in: brain, pituitary, brown fat, skeletal muscle
- Converts:
 - T₄ → T₃ inside cells (local activation)
- Important for maintaining brain and pituitary T₃ levels (feedback regulation).

C. Type III (D3)

- Found in: placenta, brain, fetal tissues
- Converts:
 - T₄ → rT₃ (inactive)
 - T₃ → T₂ (inactive)
- Main inactivation pathway of thyroid hormones.

2. Minor Metabolic Pathways

Oxidative deamination

- Produces inactive metabolites

Decarboxylation

- Further inactivates thyroid hormones

Transport of T₄ in the Blood

Protein-Bound Transport (≈99.97%)

A. Thyroxine-Binding Globulin (TBG)

- Most important & highest-affinity carrier
- Carries ~70–75% of circulating T₄
- Strong binding → slow release → acts as a hormone reservoir

B. Transthyretin (TTR) / Thyroxine-Binding Prealbumin

- Carries ~15–20% of T₄
- Lower affinity than TBG but higher than albumin

- When the thyroid gland doesn't produce the right amount of hormones, it can lead to various conditions, such as:

1. **Hyperthyroidism:** When the gland makes too much hormone.
2. **Hypothyroidism:** When the gland doesn't make enough hormone.

3. **Goiter** : An enlargement of the thyroid gland.
4. **Thyroid nodules**: Lumps on the gland.
5. **Thyroiditis**: Inflammation of the thyroid.
6. **Thyroid Cancer**: Cancer that develops in the thyroid gland.

Hypothyroidism- ^[5-7]

Definition- Thyroid hormone shortage is a frequent medical disease known as hypothyroidism. It can have major negative health repercussions and eventually result in death if left untreated. The definition of hypothyroidism is mostly biochemical because to the wide range of clinical presentation and general lack of symptom specificity.

Symptoms of Hypothyroidism:

- Enlarged thyroid gland
- Weight gain
- Slowness of speech and movement
- Dry skin
- Coarse and brittle hair
- Pallor or jaundice
- Dull facial expressions
- Bradycardia
- Pericardial effusion
- Muscle weakness.
- Memory problems
- Prolonged ankle reflex relaxation time

Causes of Hypothyroidism

- Thyroid Destruction
- Autoimmune Disease
- Thyroiditis
- Pituitary Disorder


Risk factors

- Autoimmune diseases (e.g., Type I Diabetes)
- Family History of Thyroid Disorder
- Iodine Deficiency
- Certain Medication.
- Genetic Disorder
- Pituitary Disease
- Previous thyroiditis
- Smoking



Fig No. 03 Hypothyroidism

Types of Hypothyroidism^[4,5,6]



1. Primary Hypothyroidism^[8-10]

Primary hypothyroidism is a condition where the thyroid gland itself fails to produce adequate T₄ and T₃, despite normal or high TSH from the pituitary.

Causes-

Autoimmune

- Hashimoto’s thyroiditis (most common)
- Postpartum thyroiditis
- Silent/painless thyroiditis

Iodine-related

- Iodine deficiency
- Excess iodine

Treatment-related

- Thyroidectomy (surgery)
- Radioactive iodine therapy (RAI)
- External radiation to neck (cancer treatments)

Symptoms-

General

- Fatigue, weakness
- Weight gain (mild)
- Cold intolerance
- Dry, coarse skin
- Hair loss

Cardiovascular

- Bradycardia
- Diastolic hypertension
- Hypercholesterolemia

Neurological

- Slow speech
- Depression
- Memory impairment
- Carpal tunnel syndrome

GI

- Constipation

Reproductive

- Menorrhagia
- Irregular periods
- Infertility

+ Risk Factor-

- Female sex
- Increasing age
- Family history of thyroid disease
- Other autoimmune diseases
- Iodine deficiency
- Prior neck surgery or radiation
- Postpartum period
- Use of lithium
- Genetic syndromes (Down, Turner)

+ Diagnosis

Blood Tests

1. TSH (most sensitive)
 - ↑ High in primary hypothyroidism
2. Free T₄
 - Low
3. Anti-TPO antibodies
 - Positive in Hashimoto's
4. Lipid profile
 - ↑ cholesterol, ↑ LDL

+ Treatment

A. First-Line Treatment

- **Levothyroxine (T₄)**
 - Drug of choice
 - Once daily, empty stomach
 - Dose:
 1. Typical adult: 1.6 mcg/kg/day
 2. Elderly/cardiac patients: start low (25–50 mcg/day)
- **Monitoring**
 1. Check TSH every 6–8 weeks
 2. Adjust dose to keep TSH in normal range

B. Special Situations

3. Pregnancy
 1. Increase levothyroxine dose by 30–50%

2. Keep TSH lower (<2.5 mIU/L)
- Myxoedema Coma
 1. IV Levothyroxine
 2. IV Hydrocortisone
 3. Supportive Measure

Drugs-

- Levothyroxine (T₄)
- Liothyronine (T₃)
- Combination therapy (T₄ + T₃)
- IV Levothyroxine
- Liotrix

Levothyroxine Drug Pharmacology

1. Classification

- Synthetic **thyroxine (T₄)** hormone analog.

2. Mechanism of Action

- Levothyroxine is **converted to T₃** (active form) in peripheral tissues by **deiodinases**.
- T₃ binds to **nuclear thyroid hormone receptors**, leading to:
 - Increased basal metabolic rate
 - Increased protein synthesis
 - Normalization of growth & neurological development
 - Regulation of cardiovascular, respiratory, and GI functions

3. Pharmacokinetics

Absorption

- Oral bioavailability: **60–80%**
- Best absorbed in **empty stomach** (30–60 min before breakfast)
- Absorption decreases with:
 - Food
 - Calcium, iron supplements
 - Antacids (aluminum, magnesium)
 - Proton pump inhibitors
 - Coffee
 - Cholestyramine

Distribution

- Highly protein-bound:
 - **Thyroxine-binding globulin (TBG)**
 - Transthyretin
 - Albumin

Metabolism

- Converted to T₃ by **D1 and D2 deiodinases**
- Degraded in liver, kidney, and other tissues

Half-life

- ~7 days (allows once-daily dosing)
- Longer in hypothyroidism
- Shorter in hyperthyroidism

Excretion

- Mostly in urine, some in bile

4. Indications

- **Primary hypothyroidism** (most common use)
- Secondary & tertiary hypothyroidism
- Goiter
- Myxedema coma (IV form)
- TSH suppression in thyroid cancer patients

5. Dosage

- Start low and titrate based on **TSH levels** (every 6–8 weeks).

Typical doses:

- Adults: **1.6 µg/kg/day**
- Elderly or cardiac disease: **12.5–25 µg/day initially**
- Myxedema coma: **IV 200–400 µg loading**, then maintenance

6. Adverse Effects

Usually due to **overdose** → hyperthyroid symptoms:

- Palpitations, tachycardia
- Tremors
- Heat intolerance
- Nervousness
- Weight loss
- Osteoporosis (long-term high dose)
- Atrial fibrillation
- Insomnia

7. Drug Interactions

Decreased absorption

- Calcium & iron supplements
- Sucralfate
- Proton pump inhibitors
- Antacids
- Cholestyramine
- Soy products
- Coffee

Increased metabolism

- Carbamazepine, phenytoin
- Rifampicin

Increased TBG levels (require higher dose)

- Pregnancy
- Oral contraceptives
- Estrogen therapy

Decreased TBG (lower dose needed)

- Androgens
- Glucocorticoids

8. Contraindications

- Untreated **adrenal insufficiency**
- Acute myocardial infarction
- Thyrotoxicosis

2. Secondary Hypothyroidism ^[11-13]

The underactive thyroid disease known as secondary hypothyroidism occurs when the thyroid is operating correctly but isn't getting the right signals from the hypothalamus or pituitary gland. This happens as a result of insufficient thyroid hormone production caused by the pituitary gland's inability to create enough thyroid-stimulating hormone (TSH).

Causes of Secondary Hypothyroidism

- Pituitary adenoma (non-functioning tumour)
- Pituitary surgery
- Radiation to pituitary/hypothalamus
- Pituitary infarction
- Head trauma causing pituitary damage
- Genetic defects (e.g., PIT1, PROP1 mutations)
- Pituitary infections (bacterial, fungal)
- Post-radiotherapy for brain tumours

Symptoms

- Fatigue, lethargy
- Weight gain
- Cold intolerance
- Dry skin and hair
- Constipation
- Bradycardia
- Puffy face
- Hoarse voice
- Muscle cramps
- Depression

+ Risk Factor

- History of pituitary tumour
- Previous cranial or pituitary surgery
- Cranial irradiation
- Major head trauma
- Long-term steroid therapy
- Family history of pituitary diseases
- Infiltrative systemic disease (e.g., sarcoidosis)

+ Diagnosis ^[14,15]

1. Laboratory Investigations

A. Thyroid Function Tests (TFTs)

- ↓ Free T4 (FT4) — *low or low-normal*
- ↓ _____ or _____ inappropriately _____ normal _____ TSH
(TSH is not elevated despite low thyroid hormone → hallmark of secondary hypothyroidism)

B. Additional Hormonal Tests

Because pituitary failure often affects multiple hormones:

- ↓ ACTH and cortisol (check adrenal function before giving thyroid hormone)
- ↓ LH, FSH – may show hypogonadism
- ↓ GH, IGF-1
- ↓ Prolactin (or ↑ in case of pituitary adenoma)
- Other pituitary hormones as indicated

+ Treatment ^[15,17,18]

A. Levothyroxine (T4) – Drug of Choice

- Start Levothyroxine 1.6 mcg/kg/day (adjust as needed)
- Start lower doses in elderly or cardiac patients.

B. Secondary hypothyroidism often occurs with

- ACTH deficiency → Hydrocortisone
- Gonadotropin deficiency → Sex steroid replacement (E2/Progesterone or Testosterone)
- GH deficiency → Growth hormone therapy
- Prolactin deficiency → No specific treatment required

+ Drugs-

A. Thyroid Hormone Replacement

- Levothyroxine (T4) – *Drug of choice*
- Liothyronine (T3) – rarely used
- Combination T4 + T3 – not routinely recommended

B. Drugs Used to Treat Underlying Pituitary Causes

Glucocorticoids (Hydrocortisone, Prednisolone, Dexamethasone)

C. Hormone Replacement for Associated Pituitary Deficiencies

- Hydrocortisone (for secondary adrenal insufficiency)
- Prednisolone
- Fludrocortisone (rarely needed in secondary causes)
- Estrogen + Progesterone (for females with hypogonadism)
- Testosterone (for males with hypogonadism)
- Growth Hormone (Somatropin) for GH deficiency
- Desmopressin (DDAVP)




Fig.No.04 Differences between types of Hypothyroidism

Pharmacology of Secondary Hypothyroidism Drugs

1. Classification

- Synthetic **thyroxine (T4)** hormone analog.

2. Mechanism of Action

- Levothyroxine is **converted to T3** (active form) in peripheral tissues by **deiodinases**.
- T3 binds to **nuclear thyroid hormone receptors**, leading to:
 - Increased basal metabolic rate
 - Increased protein synthesis
 - Normalization of growth & neurological development
 - Regulation of cardiovascular, respiratory, and GI functions

3. Pharmacokinetics

Absorption

- Oral bioavailability: **60–80%**
- Best absorbed in **empty stomach** (30–60 min before breakfast)
- Absorption decreases with:
 - Food
 - Calcium, iron supplements
 - Antacids (aluminum, magnesium)
 - Proton pump inhibitors
 - Coffee
 - Cholestyramine

Distribution

- Highly protein-bound:
 - **Thyroxine-binding globulin (TBG)**
 - Transthyretin
 - Albumin

Metabolism

- Converted to T3 by **D1 and D2 deiodinases**
- Degraded in liver, kidney, and other tissues

Half-life

- **~7 days** (allows once-daily dosing)
- Longer in hypothyroidism
- Shorter in hyperthyroidism

Excretion

- Mostly in urine, some in bile

4. Indications

- **Primary hypothyroidism** (most common use)
- Secondary & tertiary hypothyroidism
- Goiter
- Myxedema coma (IV form)
- TSH suppression in thyroid cancer patients

5. Dosage

- Start low and titrate based on **TSH levels** (every 6–8 weeks).

Typical doses:

- Adults: **1.6 µg/kg/day**
- Elderly or cardiac disease: **12.5–25 µg/day initially**
- Myxedema coma: **IV 200–400 µg loading**, then maintenance

6. Adverse Effects

Usually due to **overdose** → hyperthyroid symptoms:

- Palpitations, tachycardia
- Tremors
- Heat intolerance
- Nervousness
- Weight loss
- Osteoporosis (long-term high dose)
- Atrial fibrillation
- Insomnia

7. Drug Interactions

Decreased absorption

- Calcium & iron supplements
- Sucralfate
- Proton pump inhibitors
- Antacids
- Cholestyramine
- Soy products
- Coffee

Increased metabolism

- Carbamazepine, phenytoin
- Rifampicin

Increased TBG levels (require higher dose)

- Pregnancy
- Oral contraceptives
- Estrogen therapy

Decreased TBG (lower dose needed)

- Androgens
- Glucocorticoids

8. Contraindications

- Untreated **adrenal insufficiency**
- Acute myocardial infarction
- Thyrotoxicosis

Complications ^[19-22]

1. Cardiovascular Complications

Hypothyroidism significantly affects the cardiovascular system due to reduced metabolic activity and diminished sympathetic stimulation. The heart rate becomes slow (bradycardia) as thyroid hormones normally increase chronotropy and inotropy. Cardiac output falls because of decreased stroke volume and impaired myocardial contractility. Peripheral vascular resistance increases, leading to diastolic hypertension and reduced blood flow to tissues. Patients often develop hyperlipidemia especially elevated LDL and triglycerides—due to decreased lipid metabolism, which accelerates atherosclerosis and increases the risk of coronary artery disease.




Fig.No.05. Cardiovascular Complications

2. Metabolic Complications

Hypothyroidism leads to several metabolic complications due to the reduced basal metabolic rate and impaired function of metabolic pathways regulated by thyroid hormones. Patients commonly develop weight gain because of decreased energy expenditure and accumulation of fat and fluid. Hyperlipidemia is a major complication, especially elevated LDL cholesterol and triglycerides, due to reduced LDL receptor activity and slowed lipid clearance, increasing cardiovascular risk.



Fig.No.06. Metabolic Complications

3. Gastrointestinal Complications

Hypothyroidism significantly slows down the metabolic and gastrointestinal motility due to reduced thyroid hormone activity. This leads to constipation, which is the most common GI complaint, caused by decreased peristalsis and prolonged intestinal transit time. Patients may also experience abdominal bloating, discomfort, and flatulence. In severe cases, the slowed gut motility may progress to severe constipation, fecal impaction, or even paralytic ileus, especially in long-standing or untreated hypothyroidism




Fig.No.07. Gastrointestinal Complications

4. Complications in Children ^[23,24]

Hypothyroidism in children can lead to significant health complications if not diagnosed and treated early. One of the most serious consequences is impaired growth, as low thyroid hormone levels slow bone development and can result in short stature. Cognitive development may also be affected, leading to learning difficulties, poor school performance, and delayed milestones.




Fig.No.08 Complications in children's

REVIEW SUMMARY

This comprehensive review provides an in-depth overview of hypothyroidism, one of the most common endocrine disorders characterized by deficient production of thyroid hormones (T₃ and T₄). It begins by explaining the physiology of thyroid hormones, including their synthesis, metabolism, transport, and role in regulating metabolism, growth, cardiovascular activity, neurological processes, and gastrointestinal function.

The paper discusses the pathophysiology of hypothyroidism, noting that reduced thyroid hormone levels slow metabolic processes throughout the body. Two major types are highlighted: **primary hypothyroidism**, resulting from intrinsic thyroid gland dysfunction, and **secondary hypothyroidism**, caused by inadequate stimulation of the thyroid gland due to pituitary or hypothalamic failure.

Primary hypothyroidism is commonly associated with autoimmune causes such as Hashimoto's thyroiditis, iodine imbalance, and treatment-related thyroid damage. Secondary hypothyroidism arises from pituitary tumour's, surgery, radiation, infarction, trauma, or genetic defects. The review outlines clinical manifestations including fatigue, weight gain, cold intolerance, bradycardia, constipation, depression, and reproductive disturbances. Risk factors, especially autoimmune diseases, age, radiation exposure, genetic syndromes, and pituitary disorders, are also summarized.

Diagnosis relies on thyroid function tests, with **elevated TSH and low free T₄ in primary**, and **low TSH with low T₄ in secondary hypothyroidism**. Additional endocrine evaluations are essential for central (secondary) cases.

Management primarily involves **levothyroxine (T₄) replacement therapy**, with detailed pharmacology, dosing, contraindications, and monitoring guidelines presented. Secondary hypothyroidism requires both thyroid hormone replacement and treatment of associated pituitary hormone deficiencies, such as hydrocortisone for ACTH deficiency or sex steroids for hypogonadism. The review also describes the systemic complications of untreated hypothyroidism. Cardiovascular complications include bradycardia, reduced cardiac output, diastolic hypertension, and hyperlipidaemia. Metabolic disturbances mainly involve weight gain and elevated LDL levels. Gastrointestinal effects include constipation and reduced motility. Pediatric hypothyroidism can result in severe growth retardation and impaired cognitive development.

Overall, the paper consolidates key aspects of the physiology, classification, diagnosis, treatment, and complications of hypothyroidism, offering a clear and clinically relevant reference for healthcare professionals

References-

1. Brent GA. Mechanisms of thyroid hormone action. *J Clin Invest*. 2012;122(9):3035–3043.
2. Bianco AC, Dumitrescu AM, Gereben B, et al. Paradigms of thyroid hormone action. *Endocr Rev*. 2019;40(4):1000–1045.
3. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. *Endocr Rev*. 2010;31(2):139–170.
4. Hennemann G, et al. Plasma membrane transport of thyroid hormones. *Best Pract Res Clin Endocrinol Metab*. 2000;14(3):315–328.
5. Vanderpump MP. The epidemiology of thyroid disease. *Br Med Bull*. 2011;99(1):39–51.
6. Chaker L, et al. Hypothyroidism. *Lancet*. 2017;390(10101):1550–1562.
7. Fatourech V. Hypothyroidism: Clinical features and diagnosis. *UpToDate*. 2023.
8. Pearce EN, Brabant G, Duntas LH, et al. 2013 ETA Guidelines for the management of subclinical hypothyroidism. *Eur Thyroid J*. 2013;2:215–228.
9. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. *Endocr Rev*. 2008;29(1):76–131.
10. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. *Endocrine*. 2012;42:252–265.
11. Fleseriu M, Hashim IA, Karavitaki N. Central hypothyroidism: An update. *Lancet Diabetes Endocrinol*. 2021;9(12):863–875.
12. Persani L. Central hypothyroidism: Pathogenic, diagnostic, and therapeutic challenges. *J Clin Endocrinol Metab*. 2012;97(9):3068–3078.
13. Samson SL, et al. Central hypothyroidism. *Endocrinol Metab Clin North Am*. 2022;51(3):557–575.
14. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults. *Thyroid*. 2012;22(12):1200–1235.
15. Baloch Z, et al. Laboratory diagnosis of thyroid disorders. *Thyroid*. 2003;13(1):3–126.
16. Jonklass J, et al. Guidelines for the treatment of hypothyroidism. *Thyroid*. 2014;24(12):1670–1751.
17. Taylor PN, et al. Levothyroxine therapy: A global perspective. *Lancet Diabetes Endocrinol*. 2018;6(2):168–178.
18. Yavuz S, et al. Thyroid hormone replacement: Current status. *Endocr Pract*. 2013;19(5):856–863.
19. Biondi B. Heart disease and thyroid function. *Nat Rev Endocrinol*. 2019;15(8):475–490.
20. Razvi S, et al. Thyroid dysfunction and cardiovascular risk. *J Clin Endocrinol Metab*. 2018;103(5):2121–2134.
21. De Leo S, Lee SY, Braverman LE. Hypothyroidism. *Lancet*. 2016;387(10013):1550–1562.
22. Laurberg P, Andersen S, Carlé A. Hypothyroidism and the gastrointestinal system. *J Clin Endocrinol Metab*. 2020;105(9):E3310–E3320.
23. Léger J, et al. Congenital hypothyroidism: A 2020 update. *Lancet Diabetes Endocrinol*. 2020;8(6):481–492.
24. Krude H, Grüters A. Infantile and childhood hypothyroidism. *Best Pract Res Clin Endocrinol Metab*. 2002;16:183–198.



Copyright & License:

© Authors retain the copyright of this article. This work is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.